BACKGROUND: CD4 T-lymphocyte (CD4) counts are widely used to monitor response to antiretroviral therapy (ART) in resource-limited settings. However, the utility of such monitoring in terms of predicting virologic response to therapy has been little studied. METHODS: We studied participants aged 18 years and older who initiated ART in Tororo, Uganda. CD4 counts, CD4 percentages, and viral load (VL) were examined at 6-monthly intervals. Various definitions of immunologic failure were examined to identify individuals with VLs>or=50, >or=500, >or=1000, or >or=5000 copies per milliliter at 6, 12, and 18 months after treatment initiation. RESULTS: One thousand sixty-three ART-naive persons initiated ART. The proportion of individuals with virologic failure ranged between 1.5% and 16.4% for each time point. The proportion with no increase in CD4 count from baseline did not differ between those with suppressed or unsuppressed VLs at 6, 18, and 24 months after ART initiation. No increase in CD4 cell counts at 6 months had a sensitivity of 0.04 [95% confidence interval (CI) 0.00 to 0.10] and a positive predictive value of 0.03 (95% CI 0.00 to 0.09) for identifying individuals with VL>or=500 copies per milliliter at 6 months. The best measure identified was an absolute CD4 cell count<125 cells per microliter at 21 months for predicting VL>or=500 copies per milliliter at 18 months which had a sensitivity of 0.13 (95% CI 0.01 to 0.21) and a positive predictive value of 0.29 (95% CI 0.10 to 0.44). CONCLUSIONS: CD4 cell count monitoring does not accurately identify individuals with virologic failure among patients taking ART.
BACKGROUND:CD4 T-lymphocyte (CD4) counts are widely used to monitor response to antiretroviral therapy (ART) in resource-limited settings. However, the utility of such monitoring in terms of predicting virologic response to therapy has been little studied. METHODS: We studied participants aged 18 years and older who initiated ART in Tororo, Uganda. CD4 counts, CD4 percentages, and viral load (VL) were examined at 6-monthly intervals. Various definitions of immunologic failure were examined to identify individuals with VLs>or=50, >or=500, >or=1000, or >or=5000 copies per milliliter at 6, 12, and 18 months after treatment initiation. RESULTS: One thousand sixty-three ART-naive persons initiated ART. The proportion of individuals with virologic failure ranged between 1.5% and 16.4% for each time point. The proportion with no increase in CD4 count from baseline did not differ between those with suppressed or unsuppressed VLs at 6, 18, and 24 months after ART initiation. No increase in CD4 cell counts at 6 months had a sensitivity of 0.04 [95% confidence interval (CI) 0.00 to 0.10] and a positive predictive value of 0.03 (95% CI 0.00 to 0.09) for identifying individuals with VL>or=500 copies per milliliter at 6 months. The best measure identified was an absolute CD4 cell count<125 cells per microliter at 21 months for predicting VL>or=500 copies per milliliter at 18 months which had a sensitivity of 0.13 (95% CI 0.01 to 0.21) and a positive predictive value of 0.29 (95% CI 0.10 to 0.44). CONCLUSIONS:CD4 cell count monitoring does not accurately identify individuals with virologic failure among patients taking ART.
Authors: S E Rutstein; C E Golin; S B Wheeler; D Kamwendo; M C Hosseinipour; M Weinberger; W C Miller; A K Biddle; A Soko; M Mkandawire; R Mwenda; A Sarr; S Gupta; R Mataya Journal: AIDS Care Date: 2015-08-17
Authors: Theodore D Ruel; Moses R Kamya; Pelin Li; William Pasutti; Edwin D Charlebois; Teri Liegler; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong; Jane Achan Journal: J Acquir Immune Defic Syndr Date: 2011-01-01 Impact factor: 3.731
Authors: Mia Coetzer; Benjamin Westley; Allison Delong; Chhraing Tray; Dim Sophearin; Eric Nerrienet; Leeann Schreier; Rami Kantor Journal: AIDS Res Hum Retroviruses Date: 2013-04-27 Impact factor: 2.205
Authors: Janet M Raboud; Mona R Loutfy; DeSheng Su; Ahmed M Bayoumi; Marina B Klein; Curtis Cooper; Nima Machouf; Sean Rourke; Sharon Walmsley; Anita Rachlis; P Richard Harrigan; Marek Smieja; Christos Tsoukas; Julio S G Montaner; Robert S Hogg Journal: BMC Infect Dis Date: 2010-02-25 Impact factor: 3.090
Authors: Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe Journal: PLoS One Date: 2010-05-07 Impact factor: 3.240
Authors: John R Koethe; Andrew O Westfall; Dora K Luhanga; Gina M Clark; Jason D Goldman; Priscilla L Mulenga; Ronald A Cantrell; Benjamin H Chi; Isaac Zulu; Michael S Saag; Jeffrey S A Stringer Journal: PLoS One Date: 2010-03-12 Impact factor: 3.240